Literature DB >> 6397137

Host-parasite interaction in serious infections due to gram-negative bacteria.

J F Schellekens, E S Kalter, R W Vreede, J Verhoef.   

Abstract

Gram-negative rods such as Enterobacteriaceae and Pseudomonadaceae are normal habitants of the digestive tract. However, if defense mechanisms of the host are compromised by underlying diseases such as malignant neoplasms, renal insufficiency, extensive traumata, or immunosuppressive therapy, invasion of the blood-stream can occur. Gram-negative septicaemia is associated with high morbidity and mortality, despite intensive care and administration of potent antibiotics. A central role in the pathophysiology of life-threatening bacteriaemia is attributed to endotoxin, a constituent of the gram-negative cell wall. This paper reviews current concepts of septic shock, the acquisition of gram-negative bacteraemia and the role of endotoxin. It also deals with a new approach to prevention and control of severe gram-negative infections using serotherapy based on the structure of endotoxin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6397137     DOI: 10.1007/BF02386235

Source DB:  PubMed          Journal:  Antonie Van Leeuwenhoek        ISSN: 0003-6072            Impact factor:   2.271


  20 in total

1.  Epidemiology of nosocomial infection due to Gram-negative bacilli: aspects relevant to development and use of vaccines.

Authors:  W E Stamm; S M Martin; J V Bennett
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

2.  Mechanisms of endotoxin tolerance with special reference to man.

Authors:  S E Greisman; R B Hornick
Journal:  J Infect Dis       Date:  1973-07       Impact factor: 5.226

Review 3.  Bacterial endotoxins and pathogenesis.

Authors:  D C Morrison
Journal:  Rev Infect Dis       Date:  1983 Sep-Oct

4.  Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens.

Authors:  S C Schimpff; V M Young; W H Greene; G D Vermeulen; M R Moody; P H Wiernik
Journal:  Ann Intern Med       Date:  1972-11       Impact factor: 25.391

Review 5.  Symposium on infectious complications of neoplastic disease (Part II). Immunoprophylaxis and serotherapy of bacterial infections.

Authors:  L S Young
Journal:  Am J Med       Date:  1984-04       Impact factor: 4.965

6.  Influence of the Escherichia coli capsule on complement fixation and on phagocytosis and killing by human phagocytes.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Clin Invest       Date:  1980-01       Impact factor: 14.808

Review 7.  Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients.

Authors:  B E Kreger; D E Craven; W R McCabe
Journal:  Am J Med       Date:  1980-03       Impact factor: 4.965

Review 8.  Symposium on infectious complications of neoplastic disease (Part II). Chemoprophylaxis of bacterial infections in granulocytopenic patients.

Authors:  S A Henry
Journal:  Am J Med       Date:  1984-04       Impact factor: 4.965

9.  Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukaemia.

Authors:  A W Dekker; M Rozenberg-Arska; J J Sixma; J Verhoef
Journal:  Ann Intern Med       Date:  1981-11       Impact factor: 25.391

10.  Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins).

Authors:  D C Morrison; C G Cochrane
Journal:  J Exp Med       Date:  1974-09-01       Impact factor: 14.307

View more
  2 in total

1.  Cross-reactivity of monoclonal antibodies against lipopolysaccharides of gram-negative bacteria.

Authors:  J de Jongh-Leuvenink; A S Bouter; J H Marcelis; J Schellekens; J Verhoef
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

2.  Structural characterization of the lipid A component of pathogenic Neisseria meningitidis.

Authors:  V A Kulshin; U Zähringer; B Lindner; C E Frasch; C M Tsai; B A Dmitriev; E T Rietschel
Journal:  J Bacteriol       Date:  1992-03       Impact factor: 3.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.